Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| INCYTE | 12 | 25 | -0,13 % | ||
| AVADEL PHARMACEUTICALS | 10 | 6 | +1,88 % | ||
| REGENERON PHARMACEUTICALS | 9 | 22 | -0,07 % | ||
| ARCUTIS BIOTHERAPEUTICS | 9 | - | 0,00 % | ||
| BIOMARIN PHARMACEUTICAL | 8 | 12 | +0,30 % | ||
| UNITED THERAPEUTICS | 7 | 8 | +0,48 % | ||
| NEUROCRINE BIOSCIENCES | 5 | 17 | -2,72 % | ||
| IONIS PHARMACEUTICALS | 4 | - | +1,62 % | ||
| BRIDGEBIO PHARMA | 4 | - | +0,07 % | ||
| AMARIN | 3 | 5 | +2,48 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:15 | BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High | 2 | Investor's Business Daily | ||
| 13:10 | Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings? | 3 | Zacks | ||
| 13:00 | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 12:46 | Goldman Sachs meldet Long- und Short-Position in Avadel Pharmaceuticals | 4 | Investing.com Deutsch | ||
| 12:42 | Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group | 6 | Benzinga.com | ||
| 12:36 | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group | 84 | GlobeNewswire (Europe) | ADAS-Cog13 difference -12.78 (P 77.4 Weeks (17.8 Months) 'time saved' with oral blarcamesine compared to ADNI Restoring impaired Autophagy - preceding amyloid-beta and tau NEW YORK, Oct. 29, 2025... ► Artikel lesen | |
| 12:30 | BridgeBio Pharma stock climbs after positive Phase 3 results for ADH1 drug | 1 | Investing.com | ||
| 12:22 | Positive Phase-3-Studiendaten beflügeln Aktie von BridgeBio Pharma | 9 | Investing.com Deutsch | ||
| 12:12 | Ionis Pharmaceuticals GAAP EPS of -$0.80 beats by $0.43, revenue of $157M beats by $26.49M | 4 | Seeking Alpha | ||
| 12:06 | IONIS PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 12:06 | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 | 2 | GlobeNewswire (USA) | ||
| 12:06 | AMARIN CORP PLC - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 11:46 | United Therapeutics verfehlt Q3-Erwartungen trotz Rekordumsatz | 4 | Investing.com Deutsch | ||
| 11:46 | United Therapeutics: EPS verfehlt Schätzungen um 0,16 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 11:36 | United Therapeutics GAAP EPS of $7.16 beats by $0.20, revenue of $799.5M misses by $13.37M | 1 | Seeking Alpha | ||
| 11:36 | Compass Pathfinder Limited: Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors | 134 | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey... ► Artikel lesen | |
| 11:36 | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 | 31 | GlobeNewswire (Europe) | Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically... ► Artikel lesen | |
| 11:34 | UNITED THERAPEUTICS Corp - 8-K, Current Report | - | SEC Filings | ||
| 11:34 | COMPASS Pathways plc - 8-K, Current Report | - | SEC Filings | ||
| 11:32 | UNITED THERAPEUTICS Corp - 10-Q, Quarterly Report | - | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .